CYTO Stock - Altamira Therapeutics Ltd.
Unlock GoAI Insights for CYTO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | $305,616 | $63,882 | $174,475 | $-56,000 |
| Gross Profit | N/A | $-1,138,000 | $-2,176,672 | $174,475 | $-56,000 |
| Gross Margin | N/A | -372.4% | -3407.3% | 100.0% | 100.0% |
| Operating Income | $-5,916,000 | $-18,014,000 | $-5,341,421 | $-5,283,000 | $-7,259,000 |
| Net Income | $-7,270,000 | $-26,528,000 | $-17,058,443 | $-8,200,000 | $-6,632,000 |
| Net Margin | N/A | -8680.2% | -26703.1% | -4699.8% | 11842.9% |
| EPS | $-14.81 | $-582.58 | $-515.11 | $-545.41 | $-455.96 |
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Visit WebsiteEarnings History & Surprises
CYTOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 16, 2025 | — | — | — | — |
Q3 2024 | Sep 24, 2024 | $-2.38 | $-1.99 | +16.6% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-2.38 | $-2.39 | -0.2% | ✗ MISS |
Q2 2024 | May 16, 2024 | — | — | — | — |
Q4 2023 | Dec 11, 2023 | — | — | — | — |
Q3 2023 | Sep 12, 2023 | — | — | — | — |
Q3 2023 | Aug 15, 2023 | — | $-14.40 | — | — |
Q2 2023 | May 16, 2023 | — | $-3.13 | — | — |
Q2 2023 | Apr 11, 2023 | — | $-14.09 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-110.98 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-2157.47 | — | — |
Q2 2022 | Apr 12, 2022 | — | $8645.77 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-114.83 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-4195.21 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-117.41 | — | — |
Q1 2021 | Mar 31, 2021 | $-438.94 | $-168.44 | +61.6% | ✓ BEAT |
Q1 2021 | Mar 31, 2021 | — | $-115.15 | — | — |
Q3 2020 | Sep 30, 2020 | $-510.79 | $-161.93 | +68.3% | ✓ BEAT |
Q3 2020 | Sep 17, 2020 | — | $-122.64 | — | — |
Q2 2020 | Apr 16, 2020 | $-32.00 | $-85.11 | -166.0% | ✗ MISS |
Latest News
Frequently Asked Questions about CYTO
What is CYTO's current stock price?
What is the analyst price target for CYTO?
What sector is Altamira Therapeutics Ltd. in?
What is CYTO's market cap?
Does CYTO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CYTO for comparison